Santaris Pharma A/S and its partner BetaIsarna Therapeutics GmbH have signed an agreement whereby BetaIsarna gains access to certain Santaris technology to further develop its next generation product candidates.
The agreement specifies the availability of Santaris' locked nucleic acid technology, which BetaIsarna plans to use in its advancement of oligonucleotides, single-stranded DNA or RNA molecules that have a wide range of applications in genetic testing.
Under the terms of the agreement, BetaIsarna obtains rights to utilize Santaris Pharma's proprietary LNA Drug Platform to discover, develop and commercialize immunotherapeutics targeted against the cytokine Transforming Growth Factor Beta1, Beta2 and Beta3. TGF-Beta represents a pathway in oncology as its overexpression has been linked to progression and poor patient outcomes for various cancers, according to a Santaris release. It is also suspected to play a role in other diseases as well.
Santaris is expected to receive an upfront payment and is eligible for development, regulatory and sales milestones. The company will also receive a share of any sub-licensing revenues and royalties on worldwide sales of alliance products.
"We are delighted that Isarna Therapeutics selected Santaris Pharma as its partner, further validating that our LNA drug platform is the technology-of-choice for developing RNA-targeted medicines," said Dr. Henrik Oerum, chief scientific officer and VP of business development of Santaris Pharma.
Santaris was founded in 2003 in Copenhagen, Denmark and has a branch facility in San Diego.